Author Correction: Functionally selective signaling and broad metabolic benefits by novel insulin receptor partial agonists

Nat Commun. 2024 Jan 23;15(1):688. doi: 10.1038/s41467-024-44938-4.

Authors

Margaret Wu^#¹, Ester Carballo-Jane^#¹, Haihong Zhou^#¹, Peter Zafian¹, Ge Dai¹, Mindy Liu², Julie Lao², Terri Kelly¹, Dan Shao², Judith Gorski¹, Dmitri Pissarnitski¹, Ahmet Kekec¹, Ying Chen¹, Stephen F Previs¹, Giovanna Scapin¹, Yacob Gomez-Llorente¹, Scott A Hollingsworth², Lin Yan¹, Danqing Feng¹, Pei Huo¹, Geoffrey Walford³, Mark D Erion¹, David E Kelley¹, Songnian Lin⁴, James Mu⁵

Affiliations

¹ Merck & Co., Inc., Kenilworth, NJ, 07033, USA.
² Merck & Co., Inc., South San Francisco, CA, 94080, USA.
³ Merck & Co., Inc., Boston, MA, 02115, USA.
⁴ Merck & Co., Inc., Kenilworth, NJ, 07033, USA. Songnian.lin@merck.com.
⁵ Merck & Co., Inc., South San Francisco, CA, 94080, USA. yingjun_mu@merck.com.

^# Contributed equally.

No abstract available

Publication types

Published Erratum